News

BioStock published an article on 26 September 2022 about Aptahem, which can be read in full below. Aptahem has submitted applications to the regulatory authorities and to the Central Ethics [...]

Aptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Netherlands have been submitted for approval to initiate a clinical phase 1 [...]

BioStock published an article on 16 September 2022 about Aptahem, which can be read in full below. Sepsis is a life-threatening condition. Every year, 50 million people are affected by sepsis, of [...]

BioStock published an article on 31 August 2022 about Aptahem, which can be read in full below. Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of [...]

BioStock published an article on 15 August 2022 about Aptahem, which can be read in full below. BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for [...]

Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously [...]

BioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting [...]

Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the [...]

BioStock published an article on 23 May 2022 about Aptahem, which can be read in full below. Aptahem has entered into an agreement with a clinical contract research organisation in the [...]

Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to [...]